Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy

Dr. Biao Zhu: Common Comorbidities in HIV Patients and Their Antiretroviral Therapy

2023.10.12
Although antiretroviral therapy (ART) has greatly reduced the mortality associated with HIV, the morbidity of non-AIDS-related complications associated with HIV remains high. Therefore, it is crucial to understand and assess clinical decision factors for adjusting ART in the context of suppressed HIV RNA. At the recently concluded 12th International AIDS Society HIV Science Conference ( IAS 2023), Dr. A. Cozzi-Lepri of University College London reported a study (Abstract number: EPB0169) that analyzed and evaluated the risk of ART switches in the context of common comorbidities combined with HIV and suppressed HIV RNA. This journal specially invited Dr. Biao Zhu from the First Affiliated Hospital of Zhejiang University School of Medicine, China, to provide a brilliant review of this research.
Dr. Hui Wang: Second-line treatment choice for children with HIV infection

Dr. Hui Wang: Second-line treatment choice for children with HIV infection

2023.10.12
Currently, the choice of second-line antiretroviral therapy (ART) for children infected with HIV is extremely limited. At the12th International AIDS Society HIV Science Conference (IAS 2023), researchers announced the results of a significant clinical study, the CHAPAS-4 ( Abstract No. OALBB0503), focusing on the long-term treatment outcomes of second-line therapy in children with HIV infections. We specially invited Dr. Hui Wang from the Affiliated Second Hospital of Southern University of Science and Technology, China, to provide a brilliant review of this research.
Dr. YunHe: The Impact of Rapid ART Initiation on HIV Outcomes

Dr. YunHe: The Impact of Rapid ART Initiation on HIV Outcomes

2023.10.12
The concept of rapid initiation of antiretroviral therapy (ART) has been proposed for nearly 10 years, and many studies have confirmed the long-term benefits of rapid ART initiation. At the 12th International AIDS Society HIV Science Conference (IAS 2023), Thai scholar Sirinya Teeraananchai reported a study on the impact of rapid ART initiation on the health outcomes of People Living with HIV (PLWH). Dr.Yun He from the Third People's Hospital of Shenzhen, China, was specially invited to comment on the study as follows.
Dr. WeiCao: Focus on Managing HIV Complications, Further Improving Patient Survival

Dr. WeiCao: Focus on Managing HIV Complications, Further Improving Patient Survival

2023.10.12
The 12th International AIDS Society Conference on HIV Science (IAS 2023) was held from July 23-26, 2023, in Brisbane, Australia. As the largest open scientific conference in the global field of HIV/AIDS, it attracted the participation of experts, medical professionals, community organizations, and healthcare companies worldwide. Dr. Wei Cao from Peking Union Medical College Hospital, Chinese Academy of Medical Sciences, was invited to attend the conference and was interviewed on-site by Infectious Disease Frontier. We have invited Dr. Cao to share the latest developments emerging from this conference and hot topics related to HIV/AIDS treatment.
Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

Dr.HongzhouLu: NAD Management is Key for HIV Patients, Not Just Changing Medication

2023.10.12
The use of highly active antiretroviral therapy (HAART) has led to effective virological control in HIV-infected individuals, significantly reducing mortality rates and transforming AIDS into a treatable and manageable chronic disease. Today, one of the main clinical challenges is how to choose more "efficient and less toxic" treatment options to improve patients' quality of life. At the 12th International AIDS Society HIV Science Conference (IAS 2023) held recently, the first randomized controlled trial on switching to integrase strand transfer inhibitor (INSTI)-based therapy to control weight gain was reported. Infectious Disease Frontier invited Dr. Hongzhou Lu from Shenzhen Third People's Hospital, China, to interpret this trial and share insights into the current and future management of non-AIDS defining diseases (NAD) in HIV-infected individuals.
Challenges in HIV Management: Enhancing the Quality of Life for Elderly PLWH, Policy Interventions are Imperative

Challenges in HIV Management: Enhancing the Quality of Life for Elderly PLWH, Policy Interventions are Imperative

2023.10.12
From July 23-26, 2023, the 12th International AIDS Society HIV Science Conference (IAS 2023) was held in Brisbane, Australia. In recent years, with the continuous advancement of modern antiretroviral therapy (ART), the life expectancy of people living with HIV (PLWH) has significantly improved. However, the accompanying aging issue of PLWH is becoming increasingly prominent, posing unprecedented challenges to HIV management. The quality of life and living conditions of elderly PLWH have become hot topics of discussion at this conference.
Dr. WeipingCai: Long-Acting Antiretroviral Drugs Usher in a New Chapter in AIDS Care

Dr. WeipingCai: Long-Acting Antiretroviral Drugs Usher in a New Chapter in AIDS Care

2023.10.12
AIDS remains one of the most significant public health issues worldwide, with around 38 million people living with HIV (PLWH). In recent years, with the continuous advancement of antiretroviral therapy (ART), AIDS has gradually transformed into a manageable chronic disease. However, PLWH still face challenges like poor drug adherence and increased risk of resistance.